ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/medical-oncology/ovarian/recurrent/platinum-resistant
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Gynaecological / Ovarian - Recurrent / Platinum-resistant
13
trial(s) found.
NCT07546500
Advanced
Phase 3
Recruiting
A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigator's Choice of Chemotherapy in
Platinum-Resistant
High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression (
ASPENOVA
)
WEE1 inhibitor
Ovarian cancer
NSW
2031 - Randwick - Prince of Wales Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NCT07286266
Advanced
Phase 3
Recruiting
A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With
Platinum-resistant
Ovarian Cancer
anti-B7H4 antibody-drug conjugate
Ovarian cancer
NSW
2031 - Randwick - Prince of Wales Hospital
NCT07226427
Advanced
Phase 1
Recruiting
A Phase 1, First-in-Human Study of MEN2501, a KIF18A Inhibitor, as Monotherapy in Participants With
Platinum-Resistant
Ovarian Cancer (
MEN2501-01
)
KIF18A inhibitor
Platinum resistant ovarian cancer
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Cancer Research SA
NCT07218809
Advanced
Phase 3
Recruiting
A Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator's Choice Chemotherapy in FRα-low Expressing High-grade
Platinum-resistant
Epithelial Ovarian Cancer Patients (
TREVI-OC-01
)
anti-FR-alpha antibody-drug conjugate
Epithelial Ovarian Cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2217 - Kogarah - St George Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2487 - Cudgen - Tweed Valley Hospital
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
3168 - Clayton - Monash Medical Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT07214779
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-Label Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With
Platinum-Resistant
Ovarian Cancer With Cyclin E1 Overexpression (
MAESTRA-2
)
CDK2 inhibitor
Ovarian cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2500 - Wollongong - Wollongong Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4812 - Hyde Park - Icon Cancer Centre Townsville
NCT07213804
Advanced
Phase 3
Recruiting
FRAmework-01
: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) Versus Chemotherapy or Mirvetuximab Soravtansine in
Platinum-Resistant
Ovarian Cancer, and Sofetabart Mipitecan Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer.
anti-FR-alpha antibody-drug conjugate
anti-FR-alpha antibody-drug conjugate,topoisomerase inhibitor 1-payload
anti-VEGF monoclonal antibody
Carcinoma
Ovarian cancer
Primary fallopian tube serous carcinoma
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3630 - Shepparton - Goulburn Valley Health
3844 - Traralgon - Latrobe Regional Hospital
QLD
4215 - Southport - Gold Coast University Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
TAS
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre
NCT07023627
Advanced
Phase 2
Recruiting
A Phase 2, Single-Arm Study of INCB123667 in Participants With
Platinum-Resistant
Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 1) (
MAESTRA-1
)
CDK2 inhibitor
Ovarian cancer
NSW
2139 - Concord - Concord Repatriation General Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
SA
5000 - Adelaide - Cancer Research SA
5065 - Toorak Gardens - Burnside War Memorial Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NCT06690775
Advanced
Phase 2
Recruiting
Catalina-2: A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women With Advanced
Platinum-Resistant
Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6 (
TORL123-002
)
anti-CLDN6 antibody-drug conjugate
Epithelial Ovarian Cancer
Fallopian tube cancer
Ovarian cancer
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - The Prince Charles Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06682988
Advanced
Phase 2
Recruiting
A Randomized Phase 2, Open-label Study of Mirvetuximab Soravtansine in Patients With
Platinum-resistant
Advanced High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-alpha Expression Testing 2 Schedules of Administration for Dose Optimization, With a Separate Cohort to Determine Starting Dose in Patients With Moderate Hepatic Impairment (
IMGN853-0425
)
anti-FR-alpha antibody-drug conjugate
Epithelial Ovarian Cancer
Fallopian tube cancer
Primary peritoneal serous carcinoma
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2305 - New Lambton Heights - Newcastle Private Hospital
VIC
3168 - Clayton - Monash Medical Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4032 - Chermside - The Prince Charles Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06242470
Advanced
Phase 1
Recruiting
A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors (
CP-MGC026-01
)
anti-B7H3 antibody-drug conjugate,topoisomerase inhibitor 1-payload
Bladder cancer
Breast cancer
Castrate-resistant prostate cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Endometrial cancer
Gastric cancer
Gastroesophageal cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Melanoma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic adenocarcinoma
Platinum resistant ovarian cancer
Prostate adenocarcinoma
Sarcoma
Small-cell lung cancer
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06161025
Advanced
Phase 2 / Phase 3
Recruiting
A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects With
Platinum-resistant
, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (
DS6000-109
)
anti-CDH6 antibody-drug conjugate
High-grade serous ovarian cancer
NOT Ovarian cancer
NOT Ovarian mucinous carcinoma
Ovarian endometrioid adenocarcinoma
Peritoneal cancer
Primary fallopian tube serous carcinoma
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4215 - Southport - Gold Coast University Hospital
SA
5000 - South Australia - GenesisCare St Andrews Hospital
NCT06084481
Advanced
Phase 1
Recruiting
A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications (
M24-427
)
anti-cMET antibody-drug conjugate
Biliary tract cancer
Breast cancer
Epithelial Ovarian Cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Oesophageal squamous cell carcinoma
Pancreatic adenocarcinoma
Triple-negative breast cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
ACTRN12625001259437
Advanced
Phase 2
Not yet recruiting
Phase II study of disease response to Efavirenz in
platinum resistant
or heavily pretreated high-grade serous ovarian cancer (
REPURPOSE
)
non-nucleoside reverse transcriptase inhibitor
High-grade serous ovarian cancer
Primary fallopian tube serous carcinoma
Primary peritoneal serous carcinoma
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (12)
Not yet recruiting (1)
Recruitment Country and State
NSW (10)
QLD (8)
VIC (8)
SA (7)
WA (3)
TAS (2)
ACT (1)
Phase
Phase 1 (3)
Phase 2 (4)
Phase 2 / Phase 3 (1)
Phase 3 (5)
Trial Type
Advanced (13)
Cancer Therapy Class
VEGF
23%
FR-alpha
23%
CDK2
15%
WEE1
8%
B7H4
8%
PD-1
8%
PD-1/PD-L1
8%
KIF18A
8%
B7H3
8%
CDH6
8%
MET
8%
SMO
8%
Facility
2050 - Camperdown - Chris O'Brien Lifehouse (4)
2031 - Randwick - Prince of Wales Hospital (3)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (3)
3168 - Clayton - Monash Medical Centre (3)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (3)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (2)
5000 - Adelaide - Cancer Research SA (2)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (2)
3000 - Melbourne - Peter MacCallum Cancer Centre (2)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (2)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (2)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (2)
4215 - Southport - Gold Coast University Hospital (2)
4032 - Chermside - The Prince Charles Hospital (2)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (1)
6009 - Nedlands - One Clinical Research (1)
2217 - Kogarah - St George Hospital (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
2487 - Cudgen - Tweed Valley Hospital (1)
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital (1)
2605 - Garran - The Canberra Hospital (1)
3121 - Richmond - Epworth Freemasons Hospital (1)
2500 - Wollongong - Wollongong Hospital (1)
3128 - Box Hill - Box Hill Hospital - Eastern Health (1)
4812 - Hyde Park - Icon Cancer Centre Townsville (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
3630 - Shepparton - Goulburn Valley Health (1)
3844 - Traralgon - Latrobe Regional Hospital (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre (1)
2139 - Concord - Concord Repatriation General Hospital (1)
5065 - Toorak Gardens - Burnside War Memorial Hospital (1)
7000 - Hobart - Royal Hobart Hospital (1)
5042 - Bedford Park - Flinders Medical Centre (1)
6009 - Nedlands - Linear Clinical Research (1)
2305 - New Lambton Heights - Newcastle Private Hospital (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
5000 - South Australia - GenesisCare St Andrews Hospital (1)
Cancer Type
Cancer
Gynaecological cancer
Ovarian cancer
Solid tumour
Epithelial Ovarian Cancer
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Fallopian tube cancer
High-grade serous ovarian cancer
Ovarian adenocarcinoma
Ovarian serous carcinoma
Primary fallopian tube serous carcinoma
Peritoneal cancer
Platinum resistant ovarian cancer
Carcinoma
Primary peritoneal serous carcinoma
Breast cancer
Exocrine pancreatic cancer
Gastroesophageal cancer
Gastrointestinal cancer
Head and neck cancer
Head and neck squamous cell carcinoma
Hepatobiliary cancer
Hepatocellular carcinoma
Oesophageal cancer
Pancreatic adenocarcinoma
Pancreatic cancer
Pancreatobiliary cancer
Thoracic cancer
Upper gastrointestinal cancer
Bladder cancer
Castrate-resistant prostate cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Endometrial cancer
Gastric cancer
HPV-related cancer
HPV16-positive cancer
Kidney cancer
Lower gastrointestinal cancer
Lung cancer
Male genital cancers
Melanoma
Neuroendocrine carcinoma
Non-small cell lung cancer
Prostate adenocarcinoma
Prostate cancer
Respiratory tract cancer
Sarcoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Urogenital cancer
Viral-related cancer
Ovarian endometrioid adenocarcinoma
Biliary tract cancer
Breast adenocarcinoma
Oesophageal squamous cell carcinoma
Triple-negative breast cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy